Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients

Journal of Clinical Oncology

Volumn 23, Issue 24, 2005, Pages 5635-5643

  Westra, Jantine L ^a   Schaapveld, Michael ^a   Hollema, Harry ^a   De Boer, Jelle P ^a   Kraak, Marian M J ^a   De Jong, Debora ^a   Ter Elst, Arja ^a   Mulder, Nanno H ^a   Buys, Charles H C M ^a   Hofstra, Robert M W ^a   Plukker, John T M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; K RAS PROTEIN; LEVAMISOLE; PROTEIN P53; ANTINEOPLASTIC ANTIMETABOLITE; MICROSATELLITE DNA;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER INVASION; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; GENE MUTATION; GENETIC HETEROGENEITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MOLECULAR BIOLOGY; MULTIVARIATE ANALYSIS; MUTATIONAL ANALYSIS; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; UNIVARIATE ANALYSIS; ADJUVANT CHEMOTHERAPY; ANALYSIS OF VARIANCE; CHI SQUARE DISTRIBUTION; COLON TUMOR; GENETICS; GENOMIC INSTABILITY; MIDDLE AGED; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SURVIVAL; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ANALYSIS OF VARIANCE; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; FLUOROURACIL; GENES, P53; GENES, RAS; GENOMIC INSTABILITY; HUMANS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 24944525406     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.096     Document Type: Article

References (62)

1. Ionov Y, Peinado MA, Malkhosyan S, et al: Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363:558-561, 1993
2. Thibodeau SN, Bren G, Schaid D: Microsatellite instability in cancer of the proximal colon. Science 260:816-819, 1993
3. Lengauer C, Kinzler KW, Vogelstein B: Genetic instability in colorectal cancers. Nature 386:623-627, 1997
4. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61:759-767, 1990
5. Aaltonen LA, Peltomaki P, Leach FS, et al: Clues to the pathogenesis of familial colorectal cancer. Science 260:812-816, 1993
6. Breivik J, Lothe RA, Meling GI, et al: Different genetic pathways to proximal and distal colorectal cancer influenced by sex-related factors. Int J Cancer 74:664-669, 1997
7. Salahshor S, Kressner U, Pahlman L, et al: Colorectal cancer with and without microsatellite instability involves different genes. Genes Chromosomes Cancer 26:247-252, 1999
8. Samowitz WS, Holden JA, Curtin, et al: Inverse relationship between microsatellite instability and K-ras and p53 gene alterations in colon cancer. Am J Pathol 158:1517-1524, 2001
9. Elsaleh H, Powell B, McCaul K, et al: p53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 7:1343-1349, 2001
10. Lothe RA, Peltomaki P, Meling GI, et al: Genomic instability in colorectal cancer: Relationship to clinicopathologicalvariables and family history. Cancer Res 53:5849-5852, 1993
11. Kim H, Jen J, Vogelstein B, et al: Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 145:148-156, 1994
12. Jass JR, Do KA, Simms LA, et al: Morphology of sporadic colorectal cancer with DNA replication errors. Gut 42:673-679, 1998
13. Young J, Simms LA, Biden KG, et al: Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: Parallel pathways of tumorigenesis. Am J Pathol 159:2107-2116, 2001
14. Delattre O, Olschwang S, Law DJ, et al: Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 2:353-356, 1989
15. Bubb VJ, Curtis LJ, Cunningham C, et al: Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer. Oncogene 12: 2641-2649, 1996
16. Lukish JR, Muro K, DeNobile J, et al: Prognostic significance of DNA replication errors in young patients with colorectal cancer. Ann Surg 227:51-56, 1998
17. Massa MJ, Iniesta P, Gonzalez-Quevedo R, et al: Differential prognosis of replication error phenotype and loss of heterozygosity in sporadic colorectal cancer. Eur J Cancer 35:1676-1682, 1999
18. Jernvall P, Makinen MJ, Karttunen TJ, et al: Microsatellite instability: Impact on cancer progression in proximal and distal colorectal cancers. Eur J Cancer 35:197-201, 1999
19. Halling KC, French AJ, McDonnell SK, et al: Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 91:1295-1303, 1999
20. Gryfe R, Kim H, Hsieh ET, et al: Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342:69-77, 2000
21. Wright CM, Dent OF, Barker M, et al: Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg 87:1197-1202, 2000
22. Choi SW, Lee KJ, Bae YA, et al: Genetic classification of colorectal cancer based on chromosomal loss and microsatellite instability predicts survival. Clin Cancer Res 8:2311-2322, 2002
23. Watanabe T, Wu TT, Catalano PJ, et al: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344:1196-1206, 2001
24. Lim SB, Jeong SY, Lee MR, et al: Prognostic significance of microsatellite instability in sporadic colorectal cancer. Int J Colorectal Dis 19:533-537, 2004
25. Goh HS, Yao J, Smith DR: p53 point mutation and survival in colorectal cancer patients. Cancer Res 55:5217-5221, 1995
26. Smith DR, Ji CY, Goh HS: Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Br J Cancer 74:216-223, 1996
27. Pricolo VE, Finkelstein SD, Hansen K, et al: Mutated p53 gene is an independent adverse predictor of survival in colon carcinoma. Arch Surg 132:371-374, 1997
28. Borresen-Dale AL, Lothe RA, Meling GI, et al: TP53 and long-term prognosis in colorectal cancer: Mutations in the L3 zinc-binding domain predict poor survival. Clin Cancer Res 4:203-210, 1998
29. Goh HS, Elnatan J, Low CH, et al: p53 point mutation and survival in colorectal cancer patients: Effect of disease dissemination and tumor location. Int J Oncol 15:491-498, 1999
30. Kressner U, Inganas M, Byding S, et al: Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol 17:593-599, 1999
31. Tortola S, Marcuello E, Gonzalez I, et al: p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. J Clin Oncol 17:1375-1381, 1999
32. Samowitz WS, Curtin K, Ma KN, et al: Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer 99:597-602, 2002
33. Tang R, Wang JY, Fan CW, et al: p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: An analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy. Cancer Lett 210:101-109, 2004
34. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al: Dutch Colorectal Cancer Group: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638-646, 2001
35. Bleeker WA, Mulder NH, Hermans J, et al: The addition of low-dose leucovorin to the combination of 5-fluorouracil-levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer. Ann Oncol 11:547-552, 2000
36. Bleeker WA, Mulder NH, Hermans J, et al: Value and cost of follow-up after adjuvant treatment of patients with Dukes' C colonic cancer. Br J Surg 88:101-106, 2001
37. Hamilton SR and Aaltonen LA. Ed: WHO Classification of Tumours: Pathology and Genetics of Tumours of Digestive System. Geneva, Switzerland, WHO, 2000
38. Sobin LH, Ch Wittekind: UICC International Union Against Cancer TNM Classification of Malignant Tumors (ed 6). New York, NY, Wiley-Liss, 2002
39. Boland CR, Thibodeau SN, Hamilton SR, et al: A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58:5248-5257, 1998
40. Wu Y, Berends MJW, Mensink RGJ, et al: Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations. Am J Hum Genet 65:1291-1298, 1999
41. Hayes VM, Westra JL, Verlind E, et al: New comprehensive denaturing-gradient-gel-electrophoresis assay for KRAS mutation detection applied to paraffin-embedded tumors. Genes Chromosomes Cancer 29:309-314, 2000
42. Hayes VM, Bleeker W, Verlind E, et al: Comprehensive TP53-denaturing gradient gel electrophoresis mutation detection assay also applicable to archival paraffin-embedded tissue. Diagn Mol Pathol 8:2-10, 1999
43. Grambsch PM, Thernau TM: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:515-526, 1994
44. May S, Hosmer DW: A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model. Lifetime Data Anal 4:109-120, 1998
45. Olivier M, Eeles R, Hollstein M, et al: The IARC TP53 database: New online mutation analysis and recommendations to users. Hum Mutat 19:607-614, 2002
46. Andreyev HJ, Norman AR, Cunningham D, et al: Kirsten ras mutations in patients with colorectal cancer: The 'RASCAL II' study. Br J Cancer 85:692-696, 2001
47. Gafa R, Maestri I, Matteuzzi M, et al: Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability. Cancer 89: 2025-2037, 2000
48. Alexander J, Watanabe T, Wu TT, et al: Histopathological identification of colon cancer with microsatellite instability. Am J Pathol 158: 527-535, 2001
49. Costa A, Marasca R, Valentinis B, et al: p53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers. J Pathol 176:45-53, 1995
50. Hanski C, Tiecke F, Hummel M, et al: Low frequency of p53 gene mutation and protein expression in mucinous colorectal carcinomas. Cancer Lett 103:163-170, 1996
51. Elsaleh H, Powell B, Soontrapornchai P, et al: p53 gene mutation, microsatellite instability and adjuvant chemotherapy: Impact on survival of 388 patients with Dukes' C colon carcinoma. Oncology 58:52-59, 2000
52. Samowitz WS, Curtin K, Ma KN, et al: Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev 10:917-923, 2001
53. Hemminki A, Mecklin JP, Jarvinen H, et al: Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 119: 921-928, 2000
54. Elsaleh H, Joseph D, Grieu F, et al: Association of tumor site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355:1745-1750, 2000
55. Ribic CM, Sargent DJ, Moore MJ, et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247-257, 2003
56. Carethers JM, Smith EJ, Behling CA, et al: Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 126:394-401, 2004
57. Dix BR, Robbins P, Soong R, et al: The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer 59:747-751, 1994
58. Soong R, Grieu F, Robbins P, et al: p53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin Cancer Res 3:1405-1411, 1997
59. Soong R, Powell B, Elsaleh H, et al: Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma: Influence of tumor site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer 36:2053-2060, 2000
60. Kapiteijn E, Liefers GJ, Los LC, et al: Mechanisms of oncogenesis in colon versus rectal cancer. J Pathol 195:171-178, 2001
61. Goel A, Arnold CN, Niedzwiecki D, et al: Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res 63: 1608-1614, 2003
62. Johnston PG: Of what value genomics in colorectal cancer? Opportunities and challenges. J Clin Oncol 22:1538-1539, 2004